Xencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023
Xencor, Inc. (NASDAQ: XNCR) will release its third quarter 2023 financial results on November 7, 2023, after the market closes. A webcast and conference call will be held at 4:30 p.m. ET to discuss the results and provide a corporate update. The live webcast can be accessed through the Company's website, and a recording will be available for at least 30 days.
10/31/2023 - 04:01 PM
PASADENA, Calif. --(BUSINESS WIRE)--
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release third quarter 2023 financial results after the market closes on Tuesday, November 7, 2023.
Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.
The live webcast may be accessed through “Events & Presentations” in the Investors section of the Company’s website, located at investors.xencor.com . Telephone participants may register to receive a dial-in number and unique passcode that can be used to access the conference call. A recording will be available for at least 30 days.
About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and three XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20231031645708/en/
Charles Liles
cliles@xencor.com
Source: Xencor, Inc.
Xencor will release its third quarter 2023 financial results on November 7, 2023, after the market closes.
The webcast and conference call are scheduled for 4:30 p.m. ET.
The live webcast can be accessed through the 'Events & Presentations' section of Xencor's website at investors.xencor.com.
Yes, a recording of the webcast will be available for at least 30 days.
XNCR Rankings
#4337 Ranked by Stock Gains
XNCR Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Monrovia
About XNCR
antibodies by design antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. at xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. our xmab antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. this combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. the xmab® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by xencor and by pharmaceutical partners. xencor is also discovering biologics product
